AbbVie’s Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

 AbbVie’s Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

AbbVie’s Humira (adalimumab) Receives Health Canada Approval for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Shots:

  • The approval is based on SYCAMORE study assessing Humira (20mg, 40 mg, based on body wt.) + methotrexate vs methotrexate + PBO in 114 patients in a ratio (2:1) with active JIA-associated noninfectious anterior uveitis refractory to at least 12 weeks of methotrexate treatment aged > 2yrs.
  • The SYCAMORE study resulted in meeting 1EPs, with delayed treatment failure (27% vs 60%)
  • Humira (adalimumab, SC, q2w) is a mab blocking TNF-a protein targeted for an inflammatory response of immune-mediated diseases and is approved in 90 countries for 15 indications

Click here to read full press release/ article | Ref: PRNewswire | Image: MMJ Reporter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post